SEC 13F Intelligence

Managers / Q4 2020 · view latest →

Consonance Capital Management LP

CIK 0001544773 · 1370 AVENUE OF THE AMERICAS, SUITE 3301, NEW YORK, NY, 10019 · 212.660-8062

Reported Value
$1.1B
Q4 2020
Positions
38
Filings on Record
15
2019–present window
Filed
Feb 16, 2021
original filing

Summary

Consonance Capital Management LP reported $1.1B in U.S.-listed holdings across 38 positions for Q4 2020.

Its largest position, UTHR, represents 7.5% of the portfolio.

Compared with Q3 2020, the fund opened 21 new positions and exited 10.

Portfolio Metrics

Turnover
+43.3%
vs prior filed quarter
Top-10 Concentration
+62.6%
share of reported value
Largest Position
+7.5%
United Therapeutics
New / Exited
21 / 10
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q1 ’19: $1.6BQ1 ’19Q2 ’19: $1.4BQ3 ’19: $1.0BQ3 ’19Q4 ’19: $1.6BQ1 ’20: $1.3BQ1 ’20Q2 ’20: $1.7BQ3 ’20: $821MQ3 ’20Q4 ’20: $1.1BQ1 ’21: $938MQ1 ’21Q2 ’21: $831MQ3 ’21: $183MQ3 ’21Q4 ’21: $153MQ1 ’22: $59MQ1 ’22Q2 ’22: $24MQ3 ’22: $7MQ3 ’22filingsflow.com

Portfolio Composition

By security type
Common Stock: 88.4%Other: 11.6%
  • Common Stock · 88.4% · $947M
  • Other · 11.6% · $124M

Quarter-over-Quarter Changes full breakdown →

vs Q3 2020 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
UTHRUNITED THERAPEUTICS CORP DELNEW+529.0K529.0K+$80M$80M
IOVAIOVANCE BIOTHERAPEUTICS INCNEW+1.71M1.71M+$79M$79M
MIRATI THERAPEUTICS INCNEW+330.0K330.0K+$72M$72M
GMEDGLOBUS MED INCNEW+909.0K909.0K+$59M$59M
KROSKEROS THERAPEUTICS INCNEW+557.1K557.1K+$39M$39M
ARVNARVINAS INCNEW+425.0K425.0K+$36M$36M
DECIPHERA PHARMACEUTICALS INNEW+484.7K484.7K+$28M$28M
GAMIDA CELL LTDNEW+3.29M3.29M+$28M$28M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2020

38 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1UTHRUNITED THERAPEUTICS CORP DELhistory →COM7.50%$80M529.0K
2IOVAIOVANCE BIOTHERAPEUTICS INChistory →COM7.41%$79M1.71M
3MIRATI THERAPEUTICS INCCOM6.77%$72M330.0K
4TCR2 THERAPEUTICS INCCOM6.66%$71M584.9K
5ATARA BIOTHERAPEUTICS INCCOM6.48%$69M3.53M
6GNMKGENMARK DIAGNOSTICS INChistory →COM6.11%$65M4.48M
7SPRINGWORKS THERAPEUTICS INCCOM6.05%$65M893.5K
8GMEDGLOBUS MED INChistory →CL A5.54%$59M909.0K
9PTGXPROTAGONIST THERAPEUTICS INChistory →COM5.14%$55M2.73M
10MGNXMACROGENICS INChistory →COM4.91%$53M2.30M
11KROSKEROS THERAPEUTICS INChistory →COM3.67%$39M557.1K
12MERSANA THERAPEUTICS INCCOM3.48%$37M1.40M
13ARVNARVINAS INChistory →COM3.37%$36M425.0K
14KDMNKADMON HLDGS INChistory →COM2.85%$31M7.35M
15DECIPHERA PHARMACEUTICALS INCOM2.58%$28M484.7K
16GAMIDA CELL LTDSHS2.58%$28M3.29M
17AGIOAGIOS PHARMACEUTICALS INChistory →COM2.55%$27M631.2K
18IMMUNOGEN INCCOM2.12%$23M3.52M
19CASI PHARMACEUTICALS INCCOM2.09%$22M7.58M
20VERASTEM INCCOM1.55%$17M7.78M
21IVERIC BIO INCCOM1.53%$16M2.37M
22STXSSTEREOTAXIS INChistory →COM NEW1.49%$16M3.14M
23ASSEMBLY BIOSCIENCES INCCOM1.11%$12M1.97M
24CONSONANCE HFW ACQUISITION CUNIT 99/99/99990.98%$10M1.00M
25RCUSARCUS BIOSCIENCES INChistory →COM0.94%$10M387.5K
26SIO GENE THERAPIES INCCOMMON0.83%$9M3.19M
27CELLECTAR BIOSCIENCES INCCOM PAR0.79%$8M4.07M
28CTI BIOPHARMA CORPCOM0.76%$8M2.51M
29COGTCOGENT BIOSCIENCES INCCOM0.64%$7M610.0K
30DEERFIELD HEALTHCARE TECH ACUNIT 07/16/20250.35%$4M250.0K
31JIYA ACQUISITION CORPCOM CL A0.29%$3M300.0K
32ADMAADMA BIOLOGICS INCCOM0.28%$3M1.56M
33BCTG ACQUISITION CORPCOM0.19%$2M180.0K
34HELIX ACQUISITION CORPCOM CL A0.16%$2M150.0K
35FS DEV CORPCOM CL A0.10%$1M100.0K
36ATNMACTINIUM PHARMACEUTICALS INCCOM0.06%$690,00088.4K
37CEREVEL THERAPEUTICS HLDNG ICOM0.06%$658,00039.7K
38Y-MABS THERAPEUTICS INCCOM0.03%$301,0006.1K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q3 2022$7M2Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$24M7Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$59M8May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$153M15Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$183M17Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$831M32Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$938M35May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$1.1B38Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$821M27Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$1.7B32Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$1.3B31May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$1.6B35Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$1.0B30Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$1.4B30Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$1.6B26May 15, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.